Abiopharma

REPL Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Securities Fraud Class Action Involving Replimune Group, Inc.

New Form FWP - Celcuity Inc. Filed: 2025-07-30 AccNo: 0001641172-25-021475 Size: 130 KB

New Form 6-K - Evotec SE Filed: 2025-07-30 AccNo: 0001104659-25-071895 Size: 77 KB

New Form EFFECT - Cingulate Inc. Filed: 2025-07-29 AccNo: 9999999995-25-002396 Size: 1 KB

New Form 6-K - TAKEDA PHARMACEUTICAL CO LTD Filed: 2025-07-30 AccNo: 0001395064-25-000120 Size: 1 MB

New Form EFFECT - NextCure, Inc. Filed: 2025-07-29 AccNo: 9999999995-25-002394 Size: 1 KB

New Form EFFECT - RadNet, Inc. Filed: 2025-07-29 AccNo: 9999999995-25-002387 Size: 1 KB

New Form EFFECT - HOOKIPA Pharma Inc. Filed: 2025-07-29 AccNo: 9999999995-25-002379 Size: 1 KB

New Form EFFECT - HOOKIPA Pharma Inc. Filed: 2025-07-29 AccNo: 9999999995-25-002381 Size: 1 KB

Linde Commissions World-Scale Helium Storage Cavern

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT, 2016

Financial Statements And Related Announcement :: Profit Guidance

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

FDA approve CEFEPIME HYDROCHLORIDE

Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments